Genotype-Guided Antiplatelet Selection

Last Update:
About This Topic

Clopidogrel is an oral antiplatelet drug prescribed to prevent heart attacks and strokes. Clopidogrel is metabolized by CYP2C19 into its active drug form. CYP2C19 gene variants are known to be associated with increased or decreased response to clopidogrel.

Poor CYP2C19 metabolizers (a phenotype harbored by 2-4% of White and Black patients) do not metabolize clopidogrel to its active metabolite, thus putting such patients at significant risk of major adverse cardiovascular events.

Recommendation

Guide antiplatelet drug selection by CYP2C19 (3001508) genotype to reduce the risk of major adverse cardiovascular events.

Other genotyping panels that include the CYP2C19 gene are Cytochrome P450 Genotyping Panel (3001524) and Cytochrome P450 Genotyping Panel, with GeneDose Live Access (3004255).

ARUP Consult